research use only
Cat.No.S1826
| Related Targets | HDAC PARP ATM/ATR DNA-PK WRN Topoisomerase PPAR Sirtuin Casein Kinase eIF |
|---|---|
| Other DNA/RNA Synthesis Inhibitors | B02 CX-5461 (Pidnarulex) SCR7 EED226 Favipiravir (T-705) RK-33 Carmofur Triapine (3-AP) BMH-21 YK-4-279 |
|
In vitro |
Water : 30 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 303.17 | Formula | C2H8N2O3Pt |
Storage (From the date of receipt) | 2 years 4°C(in the dark) powder |
|---|---|---|---|---|---|
| CAS No. | 95734-82-0 | -- | Storage of Stock Solutions |
|
|
| Synonyms | NSC 375101D | Smiles | C(C(=O)O)O.N.N.[Pt] | ||
| Features |
This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).
|
|---|---|
| Targets/IC50/Ki |
DNA synthesis
|
| In vitro |
Nedaplatin (Aqupla) is a derivative of cisplatin for inhibition of tumor colony forming units with IC50 of 28.5 μg/mL. This compound is a platinum compound which is used for cancer chemotherapy. It inhibits the proliferation of SBC-3 cells by 98%, 93%, 75%, 54%, 27%, 6%, and 2% at a concentration of 0.005 μg/mL, 0.01 μg/mL, 0.025 μg/mL, 0.05 μg/mL, 0.1 μg/mL, 0.25 μg/mL, and 0.5 μg/mL, respectively. The IC50 value of this chemical for growth inhibition of SBC-3 cells is 0.053 μg/mL. |
| In vivo |
The sequential administration of 5-FU prior to nedaplatin or CDDP (FN or FC therapy) results in synergistically enhanced inhibition of tumour growth and prolonged survival in comparison with this compound, CDDP or 5-FU monotherapy. Combined dosing of this compound with gemcitabine results in synergistically enhanced inhibition of tumor growth in the Ma44 tumor model. This chemical plus Gemcitabine is also effective against Ma44 cells when given late in the therapy, a model for advanced disease. Potent augmentation of growth inhibition by this compound with Gemcitabine is also found with the NCI-H460 tumor model. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02964455 | Completed | Esophageal Squamous Cell Carcinoma |
Sun Yat-sen University |
November 2016 | Phase 1 |
| NCT01175460 | Completed | Esophageal Cancer |
Zhejiang Cancer Hospital |
January 2010 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.